Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Delivering the Right Therapy to the Right Patient with ADCs

Posted on August 11th, 2017 by in Pharma R&D

banner-Antibody-drug-conjugates-img-940x400 (1)

One of the most powerful tools in the fight against cancer has become the patient’s very own immune system. Among the many approaches that researchers are exploring is the use of antibody-drug conjugates (ADCs), in which the antibody acts as the vehicle that takes a bioactive drug right to the disease site.And because the delivery is so targeted, the drug, or payload, can include a cytotoxic agent that would not otherwise be safe to use systemically.
The new white paper “Antibody-drug conjugates: Converting our expanding knowledge base into successful immunotherapeutics” explores the current state of ADCs, how they function and their challenges. Adcetris, for certain lymphomas, and Kadcyla, for Her2-positive breast cancer are among the limited number of approved ADC’s, however over 40 more are in clinical development and there are even more still in the preclinical stage.

The fact that this class of immunotherapeutics is expanding so quickly is very encouraging for the future of cancer treatments, which are becoming increasingly targeted and tailored to patients. That said, optimizing the complicated mix of individual components in ADCs is difficult, so there is still a lot of work to be done in this area. Further, selection of the right antibody-drug combination requires extensive knowledge of the disease and immune system biology and mechanism of drug action. New models and methods which are better suited for ADCs must be designed and developed. Additionally, building on existing knowledge for successfully marketed immunotherapeutics can help to avoid development and regulatory hurdles to get safer, more effective immunotherapeutics to market faster.

Learn more about the components and inner workings of antibody-drug conjugates, past failures and the promise of future successes in this white paper. Read now.


All opinions shared in this post are the author’s own.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales